Grifols, ES0171996087

Grifols reports November 10, 2026. Price-to-earnings ratio is 15.16 for Grifols stock

Published on 10/16/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Its value was EUR 6.9 billion on October 16, 2026. Grifols stock costs EUR 10.17 on October 16, 2026, up 0.79 percent versus the BME prior close.

Results timing and valuation

MyPortfolio lists Grifols for November 10, 2026, with EUR 2.0 billion expected third-quarter revenue.
The company had a market capitalization of EUR 6.9 billion and a price-to-earnings ratio of 15.16 on October 16, 2026.
Grifols stock costs EUR 10.17 at Lang & Schwarz on October 16, 2026 at 3:07 p.m. CEST, 0.79 percent above the BME prior close of October 15, 2026, 15.18 percent below the 52-week high.
Laboratorios Farmaceuticos Rovi gained 1.22 percent and had a EUR 3.0 billion market capitalization on October 16, 2026.

Grifols, ES0171996087, Illustration mit AI erstellt.

Grifols is due to report its third-quarter results on November 10, 2026, with expected revenue of EUR 2.0 billion, according to MyPortfolio. At Lang & Schwarz, the stock was trading at EUR 10.17 on October 16, 2026 at 3:07 p.m. CEST, up 0.79 percent versus the BME prior close of October 15, 2026 at EUR 10.09.

EUR 11.99 marks the yearly high

The 52-week range runs from EUR 8.43 to EUR 11.99 on the BME listing. The Lang & Schwarz price sits 15.18 percent below the upper end of that range and 20.62 percent above the lower end. Trading volume reached 732,235 shares on October 16, 2026, equal to 48.80 percent of the average volume of 1,500,838 shares.

Price-to-earnings ratio and dates

Grifols had a market capitalization of EUR 6.9 billion and a price-to-earnings ratio of 15.16 on October 16, 2026. The calendar entry gives expected third-quarter earnings per share of EUR 0.28 and expected revenue of EUR 2.0 billion for November 10, 2026, according to MyPortfolio.

Comparison with peers

Grifols (BME, EUR): plus 0.79 percent, price-to-earnings ratio 15.16, market capitalization EUR 6.9 billion.

Laboratorios Farmaceuticos Rovi (BME, EUR): plus 1.22 percent, price-to-earnings ratio 16.10, market capitalization EUR 3.0 billion.

Pharma Mar (BME, EUR): plus 1.32 percent, price-to-earnings ratio 21.24, market capitalization EUR 1.2 billion.

What comes next for the stock

The November reporting date gives the market a defined calendar marker while the current quote remains below the yearly high. The scheduled revenue estimate of EUR 2.0 billion is the figure against which the next report will be measured.

Grifols stock in the afternoon

The BME listing was open when its euro quote was checked, and the stock's 0.79 percent gain remained smaller than the moves of both Rovi and Pharma Mar. The price-to-earnings ratio of 15.16 also stood below the two peer readings of 16.10 and 21.24.

At Lang & Schwarz, Grifols stock was trading at EUR 10.17 on October 16, 2026 at 3:07 p.m. CEST, 0.79 percent above the BME prior close of October 15, 2026 at EUR 10.09.

The further course of trading is shown by the continuously updated real-time quote of Grifols stock.